Shared on 03 Jun 26

Fair value Decreased 18%

TECH: Spatial Biology Platforms And Brand Simplification Will Support A Steady Forward Outlook

Bio-Techne reshapes its lineup into three simpler brands and adds new tools and software to its spatial biology platform, aiming to make advanced tissue research easier to run and analyze. But after a choppy stretch of demand and spending in biotech, analysts turn more cautious and cut what they think the business is worth.

2 views

Shared on 20 Feb 26

Fair value Increased 7.50%

TECH: Multiomic Platforms And 3D Workflows Will Support A Steady Forward Outlook

Narrative Update on Bio-Techne Analysts have adjusted their price target on Bio-Techne from $70.00 to $75.25, citing updated assumptions for revenue growth, profit margin, discount rate and future P/E that collectively support a higher assessed fair value. What’s in the News Ella benchtop immunoassay platform received CE-IVD marking and is now available for clinical use in the European Union.

18 views

Shared on 22 Jan 26

Fair value Increased 1.20%

TECH: Multiomic Automation And Buybacks Will Support A Steady Forward Outlook

Narrative Update on Bio-Techne Analysts have nudged their fair value estimate for Bio-Techne to US$70.00 per share from about US$69.17, citing updated assumptions around discount rates, long term revenue growth, profit margins and future P/E expectations. What's in the News Spatial biology brand Lunaphore is partnering with the Wyss Center for Bio and Neuroengineering in Geneva to build an automated workflow for simultaneous RNA and protein detection in 3D specimens.

3 views

Shared on 08 Jan 26

TECH: Multiomic Partnerships And Automation Will Support A Steady Forward Outlook

Analysts have kept their fair value estimate for Bio-Techne steady at about US$69.17, with small tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions driving a refined but directionally unchanged price target view. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, targeting higher resolution multiomic analysis in intact samples and broader use of spatial biology tools in research and diagnostics (Key Developments).

6 views

Shared on 01 Dec 25

TECH: Share Buyback Completion And New Partnerships Will Maintain Steady Outlook

Analysts have maintained Bio-Techne's price target at $69.17, citing minor adjustments to discount rate and forward P/E assumptions. Overall sentiment and company outlook remain steady.

4 views

Shared on 17 Nov 25

Fair value Increased 1.97%

TECH: Share Buyback Momentum Will Drive Stronger Performance Ahead

Narrative Update on Bio-Techne Analysts have increased their price target for Bio-Techne from $67.83 to $69.17, citing improved revenue growth and higher projected profit margins as key drivers behind the upward adjustment. What's in the News Bio-Techne successfully repurchased 500,000 shares between July and September 2025, completing a $124.06 million buyback under its May 2025 program (Buyback Tranche Update).

1 view

Shared on 03 Nov 25

Fair value Increased 1.12%

Analysts have nudged their price target for Bio-Techne higher, raising it by $0.75 to $67.83. They cite modest improvements in profitability expectations and a slightly increased fair value assessment.

4 views

Shared on 20 Oct 25

Fair value Increased 1.29%

Narrative Update on Bio-Techne Analysts have raised their price target for Bio-Techne from $66.23 to $67.08. This change reflects modest improvements in profit margin expectations, even though revenue growth forecasts have been slightly reduced.

2 views

Shared on 27 Aug 25

Fair value Increased 3.24%

Bio-Techne's consensus price target saw only a minimal increase to $65.31, as both future P/E and revenue growth forecasts remained largely unchanged. What's in the News Bio-Techne formed a strategic partnership to distribute Spear Bio's ultrasensitive immunoassays, enabling detection of low-abundance biomarkers in neurology, initially focusing on translational research in Alzheimer's disease.

2 views

Shared on 07 May 25

Fair value Decreased 21%

2 views

Shared on 30 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

0 views

Shared on 23 Apr 25

Fair value Decreased 3.24%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

1 view

Shared on 16 Apr 25

Fair value Decreased 0.71%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

4 views

Shared on 09 Apr 25

Fair value Decreased 1.19%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

0 views

Shared on 02 Apr 25

Fair value Increased 2.00%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

1 view

Shared on 26 Mar 25

Fair value Decreased 0.88%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

1 view

Shared on 10 Mar 25

Fair value Increased 22%

AnalystConsensusTarget has decreased future PE multiple from 50.9x to 45.3x.

2 views

TECH: Product Advances And Index Changes Will Influence Future Demand For Precision Tools

TECH: Spatial Biology Platforms And Brand Simplification Will Support A Steady Forward Outlook

TECH: Multiomic Platforms And 3D Workflows Will Support A Steady Forward Outlook

TECH: Multiomic Automation And Buybacks Will Support A Steady Forward Outlook

TECH: Multiomic Partnerships And Automation Will Support A Steady Forward Outlook

TECH: Share Buyback Completion And New Partnerships Will Maintain Steady Outlook

TECH: Share Buyback Momentum Will Drive Stronger Performance Ahead

Shared on 03 Nov 25

Shared on 20 Oct 25

Shared on 27 Aug 25

Shared on 07 May 25

Shared on 30 Apr 25

Shared on 23 Apr 25

Shared on 16 Apr 25

Shared on 09 Apr 25

Shared on 02 Apr 25

Shared on 26 Mar 25

Shared on 10 Mar 25

Fair Value vs Share Price

Recent News & Updates

Recent updates

Stay ahead on Bio-Techne

Company analysis

CEO & management